1. Carrel A. Artificial activiation of the growth in vitro of connective tissue. J Exp Med. 1913;17:14–9.
2. Westwood M, Jabbour H, Bloom S, Whitehead S, Barber T, Chapman J, et al. Ten Hot Hormones. Endocrinologist. 2005 Spring;2005(75) Feature.
3. Salmon WD, Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. The Journal of laboratory and clinical medicine. 1957 Jun;49(6):825–36. [PubMed] 4. Froesch ER, Buergi H, Ramseier EB, Bally P, Labhart A. Antibody-Suppressible and Nonsuppressible Insulin-Like Activities in Human Serum and Their Physiologic Significance. an Insulin Assay with Adipose Tissue of Increased Precision and Specificity. The Journal of clinical investigation. 1963 Nov;42:1816–34. [PMC free article] [PubMed] 5. Daughaday WH, Hall K, Raben MS, Salmon WD, Jr, van den Brande JL, van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature. 1972 Jan 14;235(5333):107. [PubMed] 6. Dulak NC, Temin HM. Multiplication-stimulating activity for chicken embryo fibroblasts from rat liver cell conditioned medium: a family of small polypeptides. Journal of cellular physiology. 1973 Apr;81(2):161–70. [PubMed] 7. Rinderknecht E, Humbel RE. Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: evidence for structural homology with insulin B chain. Proceedings of the National Academy of Sciences of the United States of America. 1976 Dec;73(12):4379–81. [PubMed] 8. Marquardt H, Todaro GJ, Henderson LE, Oroszlan S. Purification and primary structure of a polypeptide with multiplication-stimulating activity from rat liver cell cultures. Homology with human insulin-like growth factor II. The Journal of biological chemistry. 1981 Jul 10;256(13):6859–65. [PubMed] 9. Daughaday WH, Hall K, Salmon WD, Jr, Van den Brande JL, Van Wyk JJ. On the nomenclature of the somatomedins and insulin-like growth factors. Endocrinology. 1987 Nov;121(5):1911–2. [PubMed] 10. Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) Proceedings of the National Academy of Sciences of the United States of America. 1997 Nov 25;94(24):13215–20. [PubMed]
11. Denley A, Wang CC, McNeil KA, Walenkamp MJ, van Duyvenvoorde H, Wit JM, et al. Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Molecular endocrinology (Baltimore, Md. 2005 Mar;19(3):711–21.
12. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, et al. IGF-I is required for normal embryonic growth in mice. Genes & development. 1993 Dec;7(12B):2609–17. [PubMed] 13. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993 Oct 8;75(1):73–82. [PubMed] 14. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 1991 Feb 22;64(4):849–59. [PubMed] 15. LeRoith D, Roberts CT., Jr The insulin-like growth factor system and cancer. Cancer Lett. 2003 Jun 10;195(2):127–37. [PubMed] 16. Reik W, Constancia M, Dean W, Davies K, Bowden L, Murrell A, et al. Igf2 imprinting in development and disease. Int J Dev Biol. 2000;44(1):145–50. [PubMed] 17. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997 Mar;8(1):45–62. [PubMed] 18. Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002 Jun 27;417(6892):945–8. [PubMed]
19. Ohlsson R, Hedborg F, Holmgren L, Walsh C, Ekstrom TJ. Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. Development (Cambridge, England) 1994 Feb;120(2):361–8.
20. de Pagter-Holthuizen P, Jansen M, van Schaik FM, van der Kammen R, Oosterwijk C, Van den Brande JL, et al. The human insulin-like growth factor II gene contains two development-specific promoters. FEBS letters. 1987 Apr 20;214(2):259–64. [PubMed] 21. Rotwein P, Hall LJ. Evolution of insulin-like growth factor II: characterization of the mouse IGF-II gene and identification of two pseudo-exons. DNA and cell biology. 1990 Dec;9(10):725–35. [PubMed] 22. Lewis A, Reik W. How imprinting centres work. Cytogenet Genome Res. 2006;113(1–4):81–9. [PubMed] 23. Thorvaldsen JL, Duran KL, Bartolomei MS. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes & development. 1998 Dec 1;12(23):3693–702. [PubMed] 24. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet. 2001 Sep;17(9):520–7. [PubMed] 25. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature. 2000 May 25;405(6785):482–5. [PubMed]
26. Chao W, Huynh KD, Spencer RJ, Davidow LS, Lee JT. CTCF, a candidate transacting factor for X-inactivation choice. Science (New York, NY. 2002 Jan 11;295(5553):345–7.
27. Boumil RM, Ogawa Y, Sun BK, Huynh KD, Lee JT. Differential methylation of Xite and CTCF sites in Tsix mirrors the pattern of X-inactivation choice in mice. Molecular and cellular biology. 2006 Mar;26(6):2109–17. [PMC free article] [PubMed] 28. Stavropoulos N, Rowntree RK, Lee JT. Identification of developmentally specific enhancers for Tsix in the regulation of X chromosome inactivation. Molecular and cellular biology. 2005 Apr;25(7):2757–69. [PMC free article] [PubMed] 29. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.) Nature. 1961 Apr 22;190:372–3. [PubMed] 30. Thorvaldsen JL, Verona RI, Bartolomei MS. X-tra! X-tra! News from the mouse X chromosome. Developmental biology. 2006 Oct 15;298(2):344–53. [PubMed] 31. Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre. Nature genetics. 1999 Apr;21(4):400–4. [PubMed] 32. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell. 2007 Mar 23;128(6):1231–45. [PMC free article] [PubMed] 33. Do Kim J, Hinz AK, Ha Choo J, Stubbs L, Kim J. YY1 as a controlling factor for the Peg3 and Gnas imprinted domains. Genomics. 2007 Feb;89(2):262–9. [PMC free article] [PubMed] 34. Donohoe ME, Zhang LF, Xu N, Shi Y, Lee JT. Identification of a Ctcf cofactor, Yy1, for the X chromosome binary switch. Mol Cell. 2007 Jan 12;25(1):43–56. [PubMed]
35. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, et al. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science (New York, NY. 2006 Apr 14;312(5771):269–72.
36. Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS genetics. 2005 Dec;1(6):e49. [PMC free article] [PubMed] 37. Medema RH, Burgering BM. The X Factor: Skewing X Inactivation towards Cancer. Cell. 2007 Jun 29;129(7):1253–4. [PubMed] 38. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene. Cell. 2007 Jun 29;129(7):1275–86. [PMC free article] [PubMed] 39. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. The Journal of pathology. 2005 Jan;205(2):145–53. [PubMed]
40. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (New York, NY. 2007 Feb 2;315(5812):642–5.
41. Moore T, Constancia M, Zubair M, Bailleul B, Feil R, Sasaki H, et al. Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. Proceedings of the National Academy of Sciences of the United States of America. 1997 Nov 11;94(23):12509–14. [PubMed] 42. Okutsu T, Kuroiwa Y, Kagitani F, Kai M, Aisaka K, Tsutsumi O, et al. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors. J Biochem (Tokyo) 2000 Mar;127(3):475–83. [PubMed] 43. Vu TH, Chuyen NV, Li T, Hoffman AR. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer research. 2003 Apr 15;63(8):1900–5. [PubMed]
44. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Hormone and metabolic research Hormon- und Stoffwechselforschung. 2003 Nov–Dec;35(11–12):778–85.
45. Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE, Ward CW, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Molecular endocrinology (Baltimore, Md. 2004 Oct;18(10):2502–12.
46. White MF. Regulating insulin signaling and beta-cell function through IRS proteins. Canadian journal of physiology and pharmacology. 2006 Jul;84(7):725–37. [PubMed] 47. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005 Aug–Oct;16(4–5):421–39. [PubMed]
48. Scott CD, Firth SM. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Hormone and metabolic research Hormon- und Stoffwechselforschung. 2004 May;36(5):261–71.
49. Petley T, Graff K, Jiang W, Yang H, Florini J. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Hormone and metabolic research Hormon- und Stoffwechselforschung. 1999 Feb–Mar;31(2–3):70–6.
50. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003 Dec 20;107(6):873–7. [PubMed] 51. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005 Dec;4(12):988–1004. [PubMed] 52. Wilson EM, Hsieh MM, Rotwein P. Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation. The Journal of biological chemistry. 2003 Oct 17;278(42):41109–13. [PubMed] 53. Wilson EM, Rotwein P. Control of MyoD function during initiation of muscle differentiation by an autocrine signaling pathway activated by insulin-like growth factor-II. The Journal of biological chemistry. 2006 Oct 6;281(40):29962–71. [PubMed] 54. Minuto F, Palermo C, Arvigo M, Barreca AM. The IGF system and bone. J Endocrinol Invest. 2005;28(8 Suppl):8–10. [PubMed] 55. Wang ZQ, Fung MR, Barlow DP, Wagner EF. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature. 1994 Dec 1;372(6505):464–7. [PubMed] 56. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature. 1995 May 4;375(6526):34–9. [PubMed] 57. Sun FL, Dean WL, Kelsey G, Allen ND, Reik W. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature. 1997 Oct 23;389(6653):809–15. [PubMed] 58. Morison IM, Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today. 1998 Mar;4(3):110–5. [PubMed] 59. Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nature genetics. 2004 Sep;36(9):958–60. [PubMed] 60. Prawitt D, Enklaar T, Gartner-Rupprecht B, Spangenberg C, Oswald M, Lausch E, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proceedings of the National Academy of Sciences of the United States of America. 2005 Mar 15;102(11):4085–90. [PubMed]
61. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature reviews. 2006 Jan;7(1):21–33.
62. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, et al. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer research. 1999 Dec 1;59(23):5989–94. [PubMed] 63. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001 Nov 21;93(22):1698–703. [PubMed] 64. McCann AH, Miller N, O'Meara A, Pedersen I, Keogh K, Gorey T, et al. Biallelic expression of the IGF2 gene in human breast disease. Human molecular genetics. 1996 Aug;5(8):1123–7. [PubMed] 65. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer research. 2005 Dec 15;65(24):11236–40. [PubMed] 66. Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D, et al. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer research. 2005 Jun 15;65(12):5112–22. [PubMed] 67. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer research. 2005 Sep 1;65(17):7763–74. [PubMed] 68. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer research. 2005 Sep 1;65(17):7751–62. [PubMed] 69. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Human molecular genetics. 2003 Mar 1;12(5):535–49. [PubMed] 70. Jelinic P, Shaw P. Loss of imprinting and cancer. The Journal of pathology. 2007 Feb;211(3):261–8. [PubMed] 71. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002 May;2(5):361–72. [PubMed] 72. Ingram WJ, Wicking CA, Grimmond SM, Forrest AR, Wainwright BJ. Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene. 2002 Nov 21;21(53):8196–205. [PubMed] 73. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. The Journal of biological chemistry. 2000 Sep 15;275(37):28341–4. [PubMed] 74. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. The Journal of biological chemistry. 2002 Feb 15;277(7):5548–55. [PubMed] 75. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002 Dec;23(6):824–54. [PubMed] 76. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) Br J Cancer. 1995 Nov;72(5):1189–93. [PMC free article] [PubMed] 77. Rao G, Pedone CA, Valle LD, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004 Aug 12;23(36):6156–62. [PubMed] 78. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994 Jun 2;369(6479):414–8. [PubMed] 79. Sivridis E, Giatromanolaki A, Koukourakis MI. The vascular network of tumours--what is it not for? The Journal of pathology. 2003 Oct;201(2):173–80. [PubMed] 80. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551–78. [PubMed] 81. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002 Nov 1;20(21):4368–80. [PubMed] 82. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS letters. 1995 Aug 21;370(3):203–8. [PubMed] 83. Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev. 2005 Feb;16(1):77–89. [PubMed] 84. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer research. 1998 Jan 15;58(2):348–51. [PubMed] 85. Kwon YW, Kwon KS, Moon HE, Park JA, Choi KS, Kim YS, et al. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J Invest Dermatol. 2004 Jul;123(1):152–8. [PubMed] 86. Kim HJ, Kim TY. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. Br J Dermatol. 2005 Mar;152(3):418–25. [PubMed] 87. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer research. 1999 Aug 15;59(16):3915–8. [PubMed] 88. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133–40. [PubMed] 89. Guidry C, Feist R, Morris R, Hardwick CW. Changes in IGF activities in human diabetic vitreous. Diabetes. 2004 Sep;53(9):2428–35. [PubMed] 90. Lofqvist C, Chen J, Connor KM, Smith AC, Aderman CM, Liu N, et al. From the Cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proceedings of the National Academy of Sciences of the United States of America. 2007 Jun 19;104(25):10589–94. [PubMed]
91. Chen JN, Haffter P, Odenthal J, Vogelsang E, Brand M, van Eeden FJ, et al. Mutations affecting the cardiovascular system and other internal organs in zebrafish. Development (Cambridge, England) 1996 Dec;123:293–302.
92. Brown LA, Rodaway AR, Schilling TF, Jowett T, Ingham PW, Patient RK, et al. Insights into early vasculogenesis revealed by expression of the ETS-domain transcription factor Fli-1 in wild-type and mutant zebrafish embryos. Mech Dev. 2000 Feb;90(2):237–52. [PubMed] 93. Lawson ND, Vogel AM, Weinstein BM. sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell. 2002 Jul;3(1):127–36. [PubMed]
94. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development (Cambridge, England) 2001 May;128(10):1717–30.
95. Byrd N, Becker S, Maye P, Narasimhaiah R, St-Jacques B, Zhang X, et al. Hedgehog is required for murine yolk sac angiogenesis. Development (Cambridge, England) 2002 Jan;129(2):361–72.
96. Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol. 1998 Sep 24;8(19):1083–6. [PubMed] 97. Rowitch DHBSJ, Lee SM, Flax JD, Snyder EY, McMahon AP. Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci. 1999 Oct 15;19(20):8954–65. [PubMed]
98. Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, Blake Pepinsky R, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nature medicine. 2001 Jun;7(6):706–11.
99. Ruiz i Altaba A. Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development (Cambridge, England) 1999 Jun;126(14):3205–16.
100. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development (Cambridge, England) 1999 Sep;126(17):3915–24.